Amneal Pharmaceuticals (NASDAQ: AMRX) reported Q3 EPS of $0.16, $0.03 better than the analyst estimate of $0.13. Revenue for the quarter came in at $702 million versus the consensus estimate of $693.78 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2024 EPS of $0.57-$0.63, versus the consensus of $0.60. Amneal Pharmaceuticals sees FY2024 revenue of $2.7-2.8 billion, versus the consensus of $2.755 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.